Phase 1 results demonstrated effective acute pain relief while simultaneously mitigating the major risks of existing opioids by protecting against abuse and fatal overdose LYONS, Colo. , July 23, 2024 /PRNewswire/ -- Elysium Therapeutics , an emerging biopharmaceutical company establishing new standards for safety in the opioid industry by developing SMARTTM (Safer Medicines Alleviate Risks and Trauma) products, first- and best-in-class medicines to address the limitations and dangers associated with opioids and overdose rescue agents, today announced that results from a Phase 1, human-proof-of-concept study investigating the company's proprietary Oral Overdose Protected (O2PTM) hydrocodone prodrug for the treatment of moderate-to-severe acute pain will be the subject of a poster presentation at PAINWeek 2024 being held September 3-6 in Las Vegas . Poster Information: Title: SMARTTM Opioids with Unprecedented Protection Against Abuse and Oral Overdose – Human Proof-of-Concept Authors: T.
Jenkins, Ph.D., Lynn R.
Webster , M.D., Leela Vrishabhendra , M.
D., A. Greg Sturmer "Elysium's mission is to establish a new standard for opioid safety in the pharmaceutical industry, and we look forward to presenting these compelling proof-of-concept data involving our O2P hydrocodone technology, which was shown to be well-tolerated and able to deliver therapeutically relevant hydrocodone doses while safeguarding against abuse and fatal overdose," said Tom Jenkins , Ph.
D., Co-Founder and C.